by Portfolio Grader | October 12, 2012 9:00 am
The grades of six Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Acura Pharmaceuticals (NASDAQ:ACUR) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, ACUR also gets A’s. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
This week, Merck (NYSE:MRK) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Sanofi (NYSE:SNY) is seeing ratings go up from a C last week to a B this week. Sanofi-Aventis researches, develops, manufactures and markets healthcare products, particularly pharmaceuticals and human vaccines. For more information, get Portfolio Grader’s complete analysis of SNY stock.
Omeros Corp. (NASDAQ:OMER) earns a A this week, jumping up from last week’s grade of B. Omeros is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. Shares of OMER have increased 18.3% over the past month, better than the 1.8% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of OMER stock.
SciClone Pharmaceuticals‘s (NASDAQ:SCLN) ratings are looking better this week, moving up to a A from last week’s B. SciClone Pharmaceuticals is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. Wall Street has pushed the stock higher by 28.4% over the past month. The stock currently has a trailing PE Ratio of 8.00. For more information, get Portfolio Grader’s complete analysis of SCLN stock.
This week, Sucampo Pharmaceuticals‘ (NASDAQ:SCMP) ratings are up from a C last week to a B. Sucampo Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Investors have pushed the stock price up 37.4% over the past month. For more information, get Portfolio Grader’s complete analysis of SCMP stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/10/6-pharmaceutical-stocks-to-buy-now-acur-mrk-sny/
Short URL: http://invstplc.com/1dcsFF8
Copyright ©2016 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.